The combination of chemoradiation and PD-1/PD-L1 inhibitors has shown the potential to promote synergistic anti-tumor immunity through enhancing immune recognition, cytotoxic activity, and inhibiting T-cell apoptosis. Here, PDCD1 is linked to neoplasm.